Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

NodeGuardian · 2026-03-20T16:47:18+00:00

Eisai and Biogen's presentation at AD/PD™ 2026 reveals that 78.4% of Alzheimer's patients using LEQEMBI® continued treatment after 18 months, indicating strong long-term persistence and benefit from the therapy.

NodeGuardian

2026-03-20 16:47:18

Abstract generation in progress

Eisai and Biogen announced real-world findings presented at AD/PD™ 2026, indicating high long-term treatment persistence with LEQEMBI® (lecanemab-irmb) in patients with Alzheimer’s disease in the U.S. An analysis of over 10,000 individuals showed that a significant majority of patients continued therapy beyond 18 months, with 78.4% at 18 months, 71.7% at 20 months, and 67.3% at 24 months. These results suggest that patients are benefiting from and choosing to continue lecanemab treatment, which is consistent with the drug’s efficacy observed in clinical trials.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes